Candel Therapeutics, Inc. Stock News

Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC

Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.

Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Th

If investing were easy, everybody would do it, and we would all be rich. But that isn't the case.

Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Design

Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Design

NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi

NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul

NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today ann

Candel Therapeutics (CADL) entered into a loan and security agreement with Silicon Valley Bank for $25M, $20M of which will be available immediately; additional $5M will be available in…

LOS ANGELES and NEEDHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality, and Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a strategic collaboration to investigate the use of Bionauts remote-controlled microscale robots for precision delivery of Candels oncolytic viral immunotherapy agents to specific brain tumors.

Investment analysts at BMO Capital Markets assumed coverage on shares of Candel Therapeutics (NASDAQ:CADL) in a research note issued on Thursday, Price Targets.com reports. The firm set an outperform rating and a $18.00 price target on the stock. BMO Capital Markets target price suggests a potential upside of 65.59% from the stocks current price. A []